Back

The risk of cardiovascular death in systemic immune-mediated diseases: a systematic review and meta-analysis.

1 September 2025 (09:15 - 10:00)
Organised by: Logo
Congress Presentation Part of: Cardio-oncology and immunity Autoimmune/Chronic Inflammatory Disorders and Heart Disease ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Mr Lorenzo Cambini

IRCCS Humanitas Research Hospital, Milano (Italy)

6 More presentations in this session

Presentation thumbnail
To compare epicardial fat thickness with carotid intimal media thickness in predicting cardiovascular risk in patients with systemic lupus erythematosus
Doctor S. Singh (New Delhi, IN)
Abstract Slides Video
Presentation thumbnail
Heart failure as a frequent bystander in sarcoidosis - characterization of sarcoidosis patients with and without heart failure.
Miss A. Skwarek (Warsaw, PL)
Abstract Slides Video
Presentation thumbnail
Cancer increases heart failure risk in people with diabetes
Doctor J. Wong (Melbourne, AU) Professor T. Marwick (Melbourne, AU)
Abstract Slides Video
Presentation thumbnail
Thymosin mitigates immune checkpoint inhibitor-induced cardiotoxicity in cancer patients
Mr H. Dong (Nanjing, CN)
Abstract Slides Video
Presentation thumbnail
The predictive value of follow-up troponin measurements in patients treated with immune checkpoint inhibitors
Doctor M. Laufer-Perl (Tel Aviv, IL)
Abstract Slides Video

Access the full session

Session thumbnail
Cardio-oncology and immunity

The Event

Event poster

ESC Congress 2025

1 September 2025 09:15 CET
You may be interested in
thumbnail
Congress Presentation
Risk of death, thrombotic and hemorrhagic events in patients with atrial fibrillation and systemic autoimmune diseases
thumbnail
Congress Presentation
Systemic inflammation and risk of death in patients with atherosclerotic cardiovascular disease and chronic kidney disease.
thumbnail
Congress Presentation
Cardiovascular risk in autoimmune diseases: associations and interactions with traditional risk factors in a prospective population-based cohort of 450 000 individuals

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources